Global Markets For Immunoagents, Probes, And Molecular Diagnostics To Reach $60.3 Billion In 2016
November 09, 2011
Wellesley, Mass. – In a recent release, LABELING AND LINKAGE AGENTS FOR IMMUNOASSAYS AND GENE PROBES (BIO038C) from BCC Research (www.bccresearch.com), the global market for in vivo and in vitro diagnostic applications was $29.6 billion in 2010, an increase from $25.3 billion in 2009. The 2011 market is projected to be $33.5 billion, and the projection for 2011 to 2016 is that the market will grow to $60.3 billion, a 12.5% compound annual growth rate (CAGR).
The global market for immunoagents, probes, and molecular diagnostics can be broken down into six segments. The first three segments are in vitro diagnostics: research and development testing laboratories, point of care testing, and molecular diagnostic testing. The other three segments are in vivo diagnostics: immunotesting, blood banks, and other areas.
Research and development testing laboratories accounted for $5.7 billion in 2011, and in 2016 the segment should account for nearly $8.6 billion, yielding a CAGR of 8.4%.
The point of care testing segment, worth nearly $6.4 billion in 2011, should be worth nearly $9.4 billion in 2016, a CAGR of 8.1%.
The molecular diagnostic testing segment was worth $6.4 billion in 2011 and in 2016 is expected to be worth nearly $14.6 billion, a CAGR of 17.8%.
The immunotesting segment, worth nearly $10.6 billion in 2011, should be worth $20.4 billion in 2016, a CAGR of 14.1%.
The segment composed of blood banks was worth nearly $1.6 billion in 2011 and in 2016 should be worth $2.1 billion, a CAGR of 5.9%.
Lastly, the other areas were worth nearly $2.9 billion for 2011 and should be worth 5.2 billion in 2016, a CAGR of 12.7%.
Immunoassays are tests used to detect and/or quantify a specific biomolecular species in blood or a body fluid sample from a patient, or from cells in culture. The reaction that is detected is between an antibody and an antigen. The antibody (a protein) is most often a natural chemical produced by the immune system in the body of a human or animal. Antibodies, however, can be artificially made that react with a specific chemical species. The antigen is a substance or molecule that, when introduced into the body, triggers the production of a specific antibody by the normal immune system. The molecules detected by immunoassays vary widely in size, chemical and physical properties, and biological activity.
The primary areas in which immunoassays are used include clinical laboratories, clinical trials of new drugs, biotechnology research and development, the biopharmaceutical industry, and in food quality-control laboratories.
This study will be of great interest to those involved with the reagents industry, either as manufacturers and suppliers of reagents or as manufacturers of diagnostics/detection tests. It will also be of interest to end users of diagnostics/detection tests as well as to government and regulatory bodies involved in setting standards and tests that use the immunoassay, gene probe, and molecular diagnostic technologies. Research scientists interested in pursuing diagnostics and molecular detections using immunoassays and gene probes also will find this study of value.
MARKETS FOR IMMUNOAGENTS, PROBES AND MOLECULAR DIAGNOSTICS, 2009-2016
Source: BCC Research
Labeling and Linkage Agents for Immunoassays and Gene Probes( BIO038C )
Publish Date: October 2011
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC, 49 Walnut Park, Building 2, Wellesley, MA 02481, Telephone: 866-285-7215; Email: firstname.lastname@example.org as the source and publisher. Thank you.